Sosei Group Corp
TSE:4565
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (1.2), the stock would be worth ¥1 057.74 (11% upside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.1 | ¥952 |
0%
|
| 3-Year Average | 1.2 | ¥1 057.74 |
+11%
|
| 5-Year Average | 1.6 | ¥1 376.3 |
+45%
|
| Industry Average | 1.4 | ¥1 154.3 |
+21%
|
| Country Average | 1 | ¥819.06 |
-14%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| JP |
S
|
Sosei Group Corp
TSE:4565
|
86.2B JPY | 1.1 | -6.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
908.9B USD | 8.9 | 36 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.1B USD | 3.4 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 2.9 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 3.7 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 2.9 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
277.6B USD | 2.6 | 31.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 56 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 2.7 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.7B USD | 1 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.9B USD | -9.1 | 4 516.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.7 |
| Median | 1 |
| 70th Percentile | 1.5 |
| Max | 23 050 349 |
Other Multiples
Sosei Group Corp
Glance View
Sosei Group Corp. engages in the discovery, design, and development of medicines targeting G protein-coupled receptors (GPCRs). The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 198 full-time employees. The company went IPO on 2004-07-29. The pharmaceutical business is engaged in the research, development and sales of medicines, the management of regenerative medical funds, the investment in bio venture companies related to regenerative medicine, the overseas development by licensing, the promotion of commercialization, the structural analysis of GPCR, the initial lead compound creation, the candidate search by proprietary StaR technology, as well as structural base of new drugs using GPCR related basic technology drug discovery, screening, promotion of antibody drug research and development.
